Indeed, based on our results, we feel that this long-lasting salient query could be solved by focusing on TGF-β1 mRNA expression, instead of TGF-β2, and by targeting GBM tumors at first presentation, rather than at relapse. The gene discussed is TGFB2; the disease is glioblastoma.